Healthcare provider profile · identity verified

Adeline Manohar, D.O

Internal Medicine · DOWNEY, CA · NPI 1982135281

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	372	159
Amlodipine Besylate	Amlodipine Besylate	221	106
Losartan Potassium	Losartan Potassium	205	84
Lisinopril	Lisinopril	204	83
Rosuvastatin Calcium	Rosuvastatin Calcium	145	60
Metformin Hcl	Metformin Hcl	130	56
Omeprazole	Omeprazole	112	54
Levothyroxine Sodium	Levothyroxine Sodium	110	44
Glipizide	Glipizide	108	48
Albuterol Sulfate Hfa	Albuterol Sulfate	95	57
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	95	26
Hydrochlorothiazide	Hydrochlorothiazide	89	38
Metoprolol Tartrate	Metoprolol Tartrate	88	38
Simvastatin	Simvastatin	83	36
Atenolol	Atenolol	77	31
Gabapentin	Gabapentin	71	35
Meloxicam	Meloxicam	69	34
Alendronate Sodium	Alendronate Sodium	67	23
Metformin Hcl Er	Metformin Hcl	50	24
Triamcinolone Acetonide	Triamcinolone Acetonide	49	30
Potassium Chloride	Potassium Chloride	48	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	47	20
Trazodone Hcl	Trazodone Hcl	47	21
Jardiance	Empagliflozin	46	20
Furosemide	Furosemide	45	24
Pantoprazole Sodium	Pantoprazole Sodium	44	18
Terazosin Hcl	Terazosin Hcl	44	19
Ibuprofen	Ibuprofen	40	22
Tamsulosin Hcl	Tamsulosin Hcl	40	16
Humulin N	Insulin Nph Human Isophane	34	15
Lorazepam	Lorazepam	34	13
Bisoprolol Fumarate	Bisoprolol Fumarate	33	16
Ozempic	Semaglutide	33	suppressed
Ezetimibe	Ezetimibe	32	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	32	suppressed
Eliquis	Apixaban	31	suppressed
Duloxetine Hcl	Duloxetine Hcl	29	15
Hydralazine Hcl	Hydralazine Hcl	29	18
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	12
Pradaxa	Dabigatran Etexilate Mesylate	28	13
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	28	13
Wixela Inhub	Fluticasone Propion/Salmeterol	26	suppressed
Cefadroxil	Cefadroxil	25	20
Spironolactone	Spironolactone	25	11
Tramadol Hcl	Tramadol Hcl	25	suppressed
Finasteride	Finasteride	23	11
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	21	21
Azelastine Hcl	Azelastine Hcl	20	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Famotidine	Famotidine	20	12
Humulin R	Insulin Regular, Human	20	suppressed
Allopurinol	Allopurinol	19	13
Escitalopram Oxalate	Escitalopram Oxalate	19	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	19	suppressed
Hydrocortisone	Hydrocortisone	18	14
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Metoprolol Succinate	Metoprolol Succinate	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	16	suppressed
Prednisone	Prednisone	16	16
Temazepam	Temazepam	16	suppressed
Carvedilol	Carvedilol	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	15	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	14	14
Alvesco	Ciclesonide	14	11
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	13
Doxycycline Monohydrate	Doxycycline Monohydrate	14	14
Glipizide Er	Glipizide	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Clonidine Hcl	Clonidine Hcl	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Estradiol	Estradiol	12	suppressed
Lovastatin	Lovastatin	12	suppressed
Scopolamine	Scopolamine	12	suppressed
Tradjenta	Linagliptin	12	suppressed
Alprazolam	Alprazolam	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Fluticasone Propionate	Fluticasone Propionate	11	suppressed
Lidocaine	Lidocaine	11	suppressed
Methocarbamol	Methocarbamol	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error